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Introduction
A distinctive feature of systemic juvenile idiopathic
arthritis (sJIA) is its high resistance to therapy of
DMARDs and biologics (B) used as the 1st line before
the advent of IL-1 and IL-6 inhibitors.
Objectives
Analysis of experience of using B by patients (Pts) with
sJIA in a single centre during the last 10 years.
Methods
Our retrospective study included 59 Pts (20 boys, 39
girls), who used B. All Pts had diagnosis of sJIA, estab-
lished according to the ILAR classification criteria. The
clinical characteristic at the time of 1st prescription:
mean age of 6.25, range 2.0-17.75 yrs; mean disease
duration of 4.5, range 0.3-15.9 yrs; 61% of Pts had active
systemic features, 98.3% - arthritis. The previous therapy
included NSAIDs (95%), steroids (76%), DMARDs
(methotrexate (MTX) alone - 18.6%, 2 DMARDs - 68%,
3 DMARDs consecutive - 12%). As the 1st B used: inflix-
imab (INF) - 32%, tocilizumab (TCZ) - 39%, etanercept
(ETA) - 10%, adalimumab (ADA) - 9%, abatacept (ABA)
- 5%, rituximab (RTM) - 5%. 39 Pts received only 1 B:
by 12.8% - INF or ADA, 53.8%TCZ, 15.4%ETA, by 2.6%
RTM or ABA. 22 Pts received 2 B successively, the 2nd
B used: 50%TCZ, 13%ETA, 14%ADA, 14%ABA, 9%
RTM. 9 Pts received 3 B, the 3d B used: 45%TCZ, 22%
ABA, 22% canacinumab (CAN), 11%ADA. 2 Pts received
successively 4 B (INF-ADA-TCZ-ABA, INF-TCZ-ABA-
ETA). The reasons for substitution therapy were serious
adverse effects (SAE), subsequent loss of effect. We did
not use anakinra because it is not available in Russia.
Results
43 Pts continue treatment: 69.7%TCZ, 9.2%ETA, 6.9%
INF, by 4.6%ADA, ABA and CAN. The response of
therapy is more than 30-50% by the ACRpedi criteria.
Stable improvement allowed to decrease prednisolone
(PR) dose in all Pts, to cancel PR in 9.3% Pts, to cancel
NSAIDs in 14% Pts. 11 Pts have status of inactive
desease (8-TCZ, 2-INF, 1-ETA). Adverse events and
laboratory abnormalities included neutropenia (was
observed in 6 Pts receiving TCZ during 1-3 days after
infusion) and elevated transaminases (1-ETA, 4-TCZ).
6 Pts increased the weight (4-TCZ, 2-INF). We have
observed some SAE: infusion reaction (3-TCZ, 2-INF);
severe infections - sepsis (2 Pts-RTM), varicella (1-INF,
2-TCZ, 1-ABA), atypical pneumonia (1-TCZ, 1-ETA),
tuberculosis (1- ETA, 1-TCZ). Pts had worse results of
treatment in a long duration of the disease, with the
damage of hip and the cervical spine, in the presence of
synovial cysts.
Conclusion
TCZ is the best choice among B at sJIA in Pts with
ongoing systemic manifestations. The use of TNF inhibi-
tors in sJIA is characterized by high efficiency in the
initial stages of therapy and subsequent loss of effect with
a high frequency of systemic exacerbations in most Pts.
Careful monitoring provided an acceptable safety profile
of TCZ, TNF-inhibitors and ABA in the Pts with sJIA.
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